Full Text View
Tabular View
No Study Results Posted
Related Studies
Neurovascular Coupling in Eyes of Glaucoma Patients
This study is currently recruiting participants.
Verified by University Hospital, Basel, Switzerland, March 2009
First Received: January 31, 2007   Last Updated: March 19, 2009   History of Changes
Sponsored by: University Hospital, Basel, Switzerland
Information provided by: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00430209
  Purpose

We hypothesize that glaucoma patients demonstrate an impaired retinal vascular response to the flicker stimulus, and that this disturbance is predictive of the progression of glaucomatous damage. The response of a major temporal superior and inferior retinal artery and vein to a 60 seconds 12.5 Hz flicker light stimulation in 50 glaucoma patients, 50 ocular hypertensives and 50 controls (using the Retinal Vessel Analyzer) and to investigate how intraocular pressure relates to neurovascular coupling. In addition, 50 glaucoma patients and 50 ocular hypertension patients will be followed for 3 years for functional (visual field, automated perimetry with Octopus device) and morphological (retinal nerve fiber layer thickness, Optical Coherence Tomography Stratus OCT device) glaucomatous damage progression, in order to test the predictive power of the retinal vascular flicker response for glaucoma progression.


Condition
Glaucoma
Ocular Hypertension

Genetics Home Reference related topics: early-onset glaucoma
MedlinePlus related topics: Glaucoma High Blood Pressure
U.S. FDA Resources
Study Type: Observational
Study Design: Case-Only, Prospective
Official Title: Neurovascular Coupling in Eyes of Glaucoma Patients

Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 150
Study Start Date: December 2006
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Rationale: The term neurovascular coupling refers to the vascular response to an increased neuronal activity. The contact of the nerve terminals to the cortical blood vessels is mostly realized through astrocytes. A major defining property of glaucoma, cupping of the optic disc, implies tissue remodeling of the optic nerve head and involves an astrocytic responses. A malfunction of the astrocytes in glaucoma may lead not only to the hallmark of glaucoma, cupping and death of retinal ganglion cells, but also to an accompanying or even preceding disturbance in ocular neurovascular coupling. The retinal vascular bed was chosen because of the high reproducibility of the dynamic retinal vessel diameter analysis and because recently the hypoxia-inducible factor 1α was found not only in the glia of the optic nerve head but also in the retina of glaucomatous donor eyes and predominantly in retinal locations closely concordant with the locations of visual field defects recorded in these eyes, raising questions about the site of primary damage in glaucoma. It is hoped that this research project will help provide a workable tool and a model able not only to identify a risk factor for glaucoma, but in the future to explore possible therapeutic avenues to modify the course of the disease. Working hypothesis: We hypothesize that glaucoma patients demonstrate an impaired retinal vascular response to the flicker stimulus, and that this disturbance is predictive of the progression of glaucomatous damage

Subjects and Methods The present protocol intends to explore the response of a major temporal superior and inferior retinal artery and vein to a 60 seconds 12.5 Hz flicker light stimulation in 50 glaucoma patients, 50 ocular hypertensives and 50 controls (using the Retinal Vessel Analyzer) and to investigate how intraocular pressure relates to neurovascular coupling. In addition, 50 glaucoma patients and 50 ocular hypertension patients will be followed for 3 years for functional (visual field, automated perimetry with Octopus device) and morphological (retinal nerve fiber layer thickness, Optical Coherence Tomography Stratus OCT device) glaucomatous damage progression, in order to test the predictive power of the retinal vascular flicker response for glaucoma progression. Patients will be recruited in the University Eye Clinic Basel, a notification in the University Hospital of Basel and/or advertisement in a newspaper will inform potential healthy volunteers of the opportunity to participate in a scientific research project.

Study Course: Study is divided in the cross-sectional and in the cohort part. In the former, first the screening examination will be performed, to establish an eligibility of a patient / control subject for the study. Thereafter, the measurements described above will follow, which will conclude the cross-sectional part of the study. Glaucoma patients and patients with ocular hypertension will be offered a possibility to enter the cohort-study, with a 3-year follow-up embedded in the clinical routine and consisting of biannual repeated measurements outlined above.

  Eligibility

Ages Eligible for Study:   40 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

glaucoma patients ocular hypertensives normal controls

Criteria

Inclusion Criteria:

  • glaucoma
  • ocular hypertension

Exclusion Criteria:

  • highest ever measured IOP equal or higher than 30 mmHg
  • peripapillary hemorrhage
  • any suspicion of progression
  • PEX or pigment dispersion syndrome
  • a history of an acute glaucoma attack
  • chamber angle dysgenesia
  • any form of secondary glaucoma
  • diabetes
  • high levels of blood lipids
  • systemic or ocular circulatory diseases
  • medication, drugs, alcohol, smoking
  • systolic blood pressure above 145mmHg or a diastolic above 95mmHg
  • visual acuity worse than 20/25
  • high ametropia (spherical equivalent < -5 diopters or > +3 diopters)
  • astigmatism above 2 diopters
  • significant cataract
  • filtering procedures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00430209

Contacts
Contact: Konstantin Gugleta, MD +41 61 2658756 kgugleta@uhbs.ch

Locations
Switzerland, Basel-Stadt
University Eye Clinic Recruiting
Basel, Basel-Stadt, Switzerland, 4031
Contact: Selim Orgül, MD     +41 61 265 8787     sorguel@uhbs.ch    
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Selim Orgül, MD University Eye Clinic, Basel
  More Information

No publications provided

Responsible Party: University Hospital, Basel, Switzerland ( Selim Orgul )
Study ID Numbers: 083-GUK-2006-001, Swiss NatsFonds
Study First Received: January 31, 2007
Last Updated: March 19, 2009
ClinicalTrials.gov Identifier: NCT00430209     History of Changes
Health Authority: Switzerland: Swissmedic

Study placed in the following topic categories:
Glaucoma
Eye Diseases
Vascular Diseases
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:
Glaucoma
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Ocular Hypertension
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009